NRx Pharmaceuticals, Inc.
NRXP
$2.29
$0.2110.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.60M | 2.41M | 4.25M | 4.25M | 1.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.63M | 3.02M | 7.05M | 6.00M | 4.41M |
| Operating Income | -3.63M | -3.02M | -7.05M | -6.00M | -4.41M |
| Income Before Tax | -9.08M | -1.62M | -7.90M | -6.53M | -4.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.08M | -1.62M | -7.90M | -6.53M | -4.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.08M | -1.62M | -7.90M | -6.53M | -4.33M |
| EBIT | -3.63M | -3.02M | -7.05M | -6.00M | -4.41M |
| EBITDA | -3.63M | -3.02M | -7.05M | -6.00M | -4.41M |
| EPS Basic | -0.74 | -0.15 | -0.75 | -0.74 | -0.54 |
| Normalized Basic EPS | -0.34 | -0.17 | -0.47 | -0.44 | -0.34 |
| EPS Diluted | -0.74 | -0.15 | -0.75 | -0.74 | -0.54 |
| Normalized Diluted EPS | -0.34 | -0.17 | -0.47 | -0.44 | -0.34 |
| Average Basic Shares Outstanding | 12.25M | 10.97M | 10.52M | 8.85M | 8.07M |
| Average Diluted Shares Outstanding | 12.25M | 10.97M | 10.52M | 8.85M | 8.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |